Androgen receptor expression in prostate cancer cells is suppressed by activation of epidermal growth factor receptor and ErbB2

Cancer Research

Volumn 69, Issue 12, 2009, Pages 5202-5209

  Cai, Changmeng ^a   Portnoy, David C ^a   Wang, Hongyun ^a   Jiang, Xinnong ^a   Chen, Shaoyong ^a   Balk, Steven P ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ANDROGEN; ANDROGEN RECEPTOR; DACTINOMYCIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; NEU DIFFERENTIATION FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTATE SPECIFIC ANTIGEN; UO 126;

ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MESSENGER RNA SYNTHESIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN STABILITY; RECEPTOR GENE; RNA DEGRADATION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BASE SEQUENCE; CELL LINE, TUMOR; DNA PRIMERS; ENZYME ACTIVATION; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 67449158993     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-0026     Document Type: Article

References (52)

1. Mohler JL, Gregory CW, Ford OH, et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004;10:440-448 (Pubitemid 38173980)
2. Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 2005;11:4653-4657 (Pubitemid 41557182)
3. Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008;68:4447-4454
4. Stanbrough M, Bubley GJ, Ross K, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006;66:2815-2825
5. Attard G, Reid AH, Yap TA, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008;26:4563-4571
6. Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase [see comments]. Nat Med 1999;5:280-285 (Pubitemid 29124362)
7. Berger R, Lin DI, Nieto M, et al. Androgen-dependent regulation of Her-2/neu in prostate cancer cells. Cancer Res 2006;66:5723-5728 (Pubitemid 43927125)
8. Signoretti S, Montironi R, Manola J, et al. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 2000;92:1918-1925 (Pubitemid 32036922)
9. Shi Y, Brands FH, Chatterjee S, et al. Her-2/neu expression in prostate cancer: high level of expression associated with exposure to hormone therapy and androgen independent disease. J Urol 2001;166:1514-1519 (Pubitemid 32862230)
10. Reese DM, Small EJ, Magrane G, Waldman FM, Chew K, Sudilovsky D. HER2 protein expression and gene amplification in androgen-independent prostate cancer. Am J Clin Pathol 2001;116:234-239 (Pubitemid 33044328)
11. Calvo BF, Levine AM, Marcos M, et al. Human epidermal receptor-2 expression in prostate cancer. Clin Cancer Res 2003;9:1087-1097 (Pubitemid 36323716)
12. Savinainen KJ, Saramaki OR, Linja MJ, et al. Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer. Am J Pathol 2002;160:339-345 (Pubitemid 34052294)
13. Osman I, Scher HI, Drobnjak M, et al. HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. Clin Cancer Res 2001;7:2643-2647 (Pubitemid 32911366)
14. Leung HY, Weston J, Gullick WJ, Williams G. A potential autocrine loop between heregulin-α and erbB-3 receptor in human prostatic adenocarcinoma. Br J Urol 1997;79:212-216 (Pubitemid 127798049)
15. Culig Z, Hobisch A, Cronauer MV, et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994;54:5474-5478 (Pubitemid 24978134)
16. Reinikainen P, Palvimo JJ, Janne OA. Effects of mitogens on androgen receptor-mediated transactivation. Endocrinology 1996;137:4351-4357 (Pubitemid 26321884)
17. Orio F, Jr., Terouanne B, Georget V, et al. Potential action of IGF-1 and EGF on androgen receptor nuclear transfer and transactivation in normal and cancer human prostate cell lines. Mol Cell Endocrinol 2002;198:105-114 (Pubitemid 36169940)
18. Gregory CW, Fei X, Ponguta LA, et al. Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. J Biol Chem 2004;279:7119-7130 (Pubitemid 38248859)
19. Weber MJ, Gioeli D. Ras signaling in prostate cancer progression. J Cell Biochem 2004;91:13-25.
20. Kraus S, Gioeli D, Vomastek T, Gordon V, Weber MJ. Receptor for activated C kinase 1 (RACK1) and Src regulate the tyrosine phosphorylation and function of the androgen receptor. Cancer Res 2006;66:11047-11054 (Pubitemid 44877005)
21. Guo Z, Dai B, Jiang T, et al. Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell 2006;10:309-319 (Pubitemid 44512189)
22. Mellinghoff IK, Tran C, Sawyers CL. Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts. Cancer Res 2002;62:5254-5259 (Pubitemid 35024599)
23. Gregory CW, Whang YE, McCall W, et al. Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth. Clin Cancer Res 2005;11:1704-1712 (Pubitemid 40471831)
24. Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J, Sawyers CL. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 2004;6:517-527 (Pubitemid 39469987)
25. Liu Y, Majumder S, McCall W, et al. Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer. Cancer Res 2005;65:3404-3409 (Pubitemid 40524626)
26. Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, Chang C. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci U S A 1999;96:5458-5463 (Pubitemid 29234639)
27. Wen Y, Hu MC, Makino K, et al. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res 2000;60:6841-6845 (Pubitemid 32059149)
28. Henttu P, Vihko P. Growth factor regulation of gene expression in the human prostatic carcinoma cell line LNCaP. Cancer Res 1993;53:1051-1058 (Pubitemid 23087906)
29. Adam RM, Kim J, Lin J, et al. Heparin-binding epidermal growth factor-like growth factor stimulates androgen-independent prostate tumor growth and antagonizes androgen receptor function. Endocrinology 2002;143:4599-4608 (Pubitemid 35397601)
30. Cinar B, De Benedetti A, Freeman MR. Post-transcriptional regulation of the androgen receptor by Mammalian target of rapamycin. Cancer Res 2005;65:2547-2553 (Pubitemid 40490049)
31. Hakariya T, Shida Y, Sakai H, Kanetake H, Igawa T. EGFR signaling pathway negatively regulates PSA expression and secretion via the PI3K-Akt pathway in LNCaP prostate cancer cells. Biochem Biophys Res Commun 2006;342:92-100. (Pubitemid 43247364)
32. Lin HK, Yeh S, Kang HY, Chang C. Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proc Natl Acad Sci U S A 2001;98:7200-7205 (Pubitemid 32567926)
33. Lin HK, Wang L, Hu YC, Altuwaijri S, Chang C. Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. EMBO J 2002;21:4037-4048 (Pubitemid 34857436)
34. Lin HK, Hu YC, Yang L, et al. Suppression versus induction of androgen receptor functions by the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer LNCaP cells with different passage numbers. J Biol Chem 2003;278:50902-50907 (Pubitemid 38020321)
35. Gaughan L, Logan IR, Neal DE, Robson CN. Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation. Nucleic Acids Res 2005;33:13-26. (Pubitemid 40276925)
36. Taneja SS, Ha S, Swenson NK, et al. Cell-specific regulation of androgen receptor phosphorylation in vivo. J Biol Chem 2005;280:40916-40924 (Pubitemid 41780585)
37. Krongrad A, Wilson CM, Wilson JD, Allman DR, McPhaul MJ. Androgen increases androgen receptor protein while decreasing receptor mRNA in LNCaP cells. Mol Cell Endocrinol 1991;76:79-88.
38. Kumar MV, Jones EA, Grossmann ME, Blexrud MD, Tindall DJ. Identification and characterization of a suppressor element in the 5′-flanking region of the mouse androgen receptor gene. Nucleic Acids Res 1994;22:3693-3698 (Pubitemid 24299847)
39. Grossmann ME, Lindzey J, Kumar MV, Tindall DJ. The mouse androgen receptor is suppressed by the 5′-untranslated region of the gene. Mol Endocrinol 1994;8:448-455 (Pubitemid 24114735)
40. Wang LG, Johnson EM, Kinoshita Y, et al. Androgen receptor overexpression in prostate cancer linked to Purα loss from a novel repressor complex. Cancer Res 2008;68:2678-2688 (Pubitemid 351556265)
41. Inoue T, Leman ES, Yeater DB, Getzenberg RH. The potential role of purine-rich element binding protein (PUR) α as a novel treatment target for hormone-refractory prostate cancer. Prostate 2008;68:1048-1056 (Pubitemid 351875176)
42. Wang LG, Ossowski L, Ferrari AC. Androgen receptor level controlled by a suppressor complex lost in an androgen-independent prostate cancer cell line. Oncogene 2004;23:5175-5184 (Pubitemid 38980350)
43. Taplin ME, Bubley GJ, Shuster TD, et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995;332:1393-1398
44. Holzbeierlein J, Lal P, LaTulippe E, et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004;164:217-227 (Pubitemid 38364606)
45. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33-39 (Pubitemid 38524696)
46. Yeap BB, Wilce JA, Leedman PJ. The androgen receptor mRNA. BioEssays 2004;26:672-682 (Pubitemid 38758345)
47. Yeap BB, Voon DC, Vivian JP, et al. Novel binding of HuR and poly(C)-binding protein to a conserved UCrich motif within the 3′-untranslated region of the androgen receptor messenger RNA. J Biol Chem 2002;277:27183-27192
48. Kumar MV, Jones EA, Felts SJ, et al. Characterization of a TPA-response element in the 5′-flanking region of the androgen receptor gene. J Androl 1998;19:595-602. (Pubitemid 28498451)
49. Yang L, Xie S, Jamaluddin MS, et al. Induction of androgen receptor expression by phosphatidylinositol 3-kinase/Akt downstream substrate, FOXO3a, and their roles in apoptosis of LNCaP prostate cancer cells. J Biol Chem 2005;280:33558-33565 (Pubitemid 41397156)
50. Lindzey J, Grossmann M, Kumar MV, Tindall DJ. Regulation of the 5′-flanking region of the mouse androgen receptor gene by cAMP and androgen. Mol Endocrinol 1993;7:1530-1540 (Pubitemid 24034235)
51. Mizokami A, Yeh SY, Chang C. Identification of 3′,5′-cyclic adenosine monophosphate response element and other cis-acting elements in the human androgen receptor gene promoter. Mol Endocrinol 1994;8:77-88. (Pubitemid 24985670)
52. Grad JM, Dai JL, Wu S, Burnstein KL. Multiple androgen response elements and a Myc consensus site in the androgen receptor (AR) coding region are involved in androgen-mediated up-regulation of AR messenger RNA. Mol Endocrinol 1999;13:1896-1911 (Pubitemid 30645263)